Literature DB >> 20814247

Small-molecule inducer of cancer cell polyploidy promotes apoptosis or senescence: Implications for therapy.

Christian Tovar1, Brian Higgins, Dayanand Deo, Kenneth Kolinsky, Jin-Jun Liu, David C Heimbrook, Lyubomir T Vassilev.   

Abstract

Polyploidy results from deregulated cell division and has been considered an undesirable event leading to increased mutation rate and cancer development. However, polyploidy may also render cancer cells more vulnerable to chemotherapy. Here, we identify a small-molecule inducer of polyploidy, R1530, which interferes with tubulin polymerization and mitotic checkpoint function in cancer cells, leading to abortive mitosis, endoreduplication and polyploidy. In the presence of R1530, polyploid cancer cells underwent apoptosis or became senescent which translated into potent in vitro and in vivo efficacy. Normal proliferating cells were resistant to R1530-induced polyploidy thus supporting the rationale for cancer therapy by induced polyploidy. Mitotic checkpoint kinase BubR1 was found downregulated during R1530-induced exit from mitosis, a likely consequence of PLK4 inhibition. BubR1 knockdown in the presence of nocodazole induced an R1530-like phenotype, suggesting that BubR1 plays a key role in polyploidy induction by R1530 and could be exploited as a target for designing more specific polyploidy inducers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20814247     DOI: 10.4161/cc.9.16.12732

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  14 in total

Review 1.  Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.

Authors:  Kinsie E Arnst; Souvik Banerjee; Hao Chen; Shanshan Deng; Dong-Jin Hwang; Wei Li; Duane D Miller
Journal:  Med Res Rev       Date:  2019-02-11       Impact factor: 12.944

2.  Discovery of a highly potent, orally active mitosis/angiogenesis inhibitor r1530 for the treatment of solid tumors.

Authors:  Jin-Jun Liu; Brian Higgins; Grace Ju; Kenneth Kolinsky; Kin-Chun Luk; Kathryn Packman; Giacomo Pizzolato; Yi Ren; Kshitij Thakkar; Christian Tovar; Zhuming Zhang; Peter M Wovkulich
Journal:  ACS Med Chem Lett       Date:  2013-01-15       Impact factor: 4.345

3.  Spindle Assembly Disruption and Cancer Cell Apoptosis with a CLTC-Binding Compound.

Authors:  Michael J Bond; Marina Bleiler; Lauren E Harrison; Eric W Scocchera; Masako Nakanishi; Narendran G-Dayanan; Santosh Keshipeddy; Daniel W Rosenberg; Dennis L Wright; Charles Giardina
Journal:  Mol Cancer Res       Date:  2018-05-16       Impact factor: 5.852

4.  Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFĸB pathway.

Authors:  Ilana Chefetz; Jennie C Holmberg; Ayesha B Alvero; Irene Visintin; Gil Mor
Journal:  Cell Cycle       Date:  2011-07-01       Impact factor: 4.534

5.  BMS-777607 promotes megakaryocytic differentiation and induces polyploidization in the CHRF-288-11 cells.

Authors:  Retno Wahyu Nurhayati; Yoshihiro Ojima; Masahito Taya
Journal:  Hum Cell       Date:  2014-10-11       Impact factor: 4.174

Review 6.  Roles of eukaryotic topoisomerases in transcription, replication and genomic stability.

Authors:  Yves Pommier; Yilun Sun; Shar-Yin N Huang; John L Nitiss
Journal:  Nat Rev Mol Cell Biol       Date:  2016-09-21       Impact factor: 113.915

Review 7.  Recent progress in targeting cancer.

Authors:  Zoya N Demidenko; James A McCubrey
Journal:  Aging (Albany NY)       Date:  2011-12       Impact factor: 5.682

Review 8.  Targeting tumor cell senescence and polyploidy as potential therapeutic strategies.

Authors:  Tareq Saleh; Valerie J Carpenter; Sarah Bloukh; David A Gewirtz
Journal:  Semin Cancer Biol       Date:  2020-12-20       Impact factor: 17.012

9.  Cell fusion induced by ERVWE1 or measles virus causes cellular senescence.

Authors:  Anna Chuprin; Hilah Gal; Tal Biron-Shental; Anat Biran; Aliza Amiel; Shmuel Rozenblatt; Valery Krizhanovsky
Journal:  Genes Dev       Date:  2013-11-01       Impact factor: 11.361

Review 10.  Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Richard A Franklin; Giuseppe Montalto; Melchiorre Cervello; Massimo Libra; Saverio Candido; Grazia Malaponte; Maria C Mazzarino; Paolo Fagone; Ferdinando Nicoletti; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Francesca Chiarini; Camilla Evangelisti; Lucio Cocco; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.